LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Oncology · LCD-L38985
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertCPT procedure code
0005U
Medicare payment
$760.00
2026 Clinical Laboratory Fee Schedule
Source: CMS Clinical Laboratory Fee Schedule (2026). CMS fee schedules ↗
National amount before geographic adjustment. Your MAC's locality rate will differ.
Code definition
Code
0005U
Code system
CPT (Current Procedural Terminology)
This CPT code is not in our curated reference. CPT codes are maintained by the American Medical Association (AMA). Full descriptions require an AMA license.
Category
—
Short description sourced from CMS publicly available fee schedule data. Full CPT descriptions are copyright AMA. Not a substitute for the official CPT codebook.
Policy activity for CPT 0005U
CLV Intelligence is tracking 9 policy changes that cite CPT 0005U between 2026-06-05 and 2026-09-12, drawn from 9 LCD/NCD coverage updates. The changes span Clinical Laboratory, Oncology and Urology. 6 are flagged critical or high priority.
- LCD/NCD coverage updates
- 9
Counts reflect the source documents CLV has matched to CPT 0005U to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.
Policy changes matched to 0005U
Matched to this code by CLV analysis of each policy. The linked source document is authoritative.
High
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Clinical Laboratory · LCD-L36256
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Clinical Laboratory · LCD-L36021
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Oncology · LCD-L39005
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L38997: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — CGS
Urology · LCD-L38997
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Clinical Laboratory · LCD-L35160
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L39042: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — WPS
Oncology · LCD-L39042
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L37792: 4Kscore Test Algorithm — Novitas
Clinical Laboratory · LCD-L37792
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertLCD L37798: 4Kscore Test Algorithm — First Coast
Oncology · LCD-L37798
Government source· CMS / MACverify ↗Full analysis available with a CLV subscription.
View alertAudit documentation
Building an audit file that includes CPT 0005U?
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
See audit packs — $349One-time purchase · not a subscription
Get alerts when policy changes affect 0005U
Free weekly digest — no subscription required.
Look up another code
Search ICD-10, HCPCS, or CPT codes with related reimbursement alerts.